On December 16, 2022, analytical firm “Morgan Stanley” published a latest price target for Moderna (MRNA) stock of $209.00 for the next 12 months. 28 analyst firms have released forecasts for Moderna (MRNA) stock over the past year. The consensus rating of analytical firms is “Buy”. Analysts’ average target price is $177.00. See the table below for the latest price targets and analyst forecasts for Moderna (MRNA) shares.